Physician profile
Jamison Allen
NPI 1184614760
$12,987.10
in general payments reported to CMS, 2019-2025
47 companies · $2,551 in 2025
The $2,551 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,070 · 2020: $1,281 · 2021: $1,767 · 2022: $2,156 · 2023: $1,946 · 2024: $2,216 · 2025: $2,551.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,713.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,712.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,063.46 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $1,784.82 | 2019-2025 | |
| Lilly USA, LLC | $1,207.22 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $977.43 | 2019-2025 | Ubrelvy, Qulipta, Vraylar |
| Glaxosmithkline, LLC. | $924.33 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $784.08 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $743.25 | 2019-2025 | Evenity, Prolia, Repatha |
| Janssen Pharmaceuticals, INC | $567.27 | 2019-2025 | Spravato, Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $517.09 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Amarin Pharma, INC. | $404.84 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $343.09 | 2019-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Watermark Medical, INC. | $276.65 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $271.17 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $215.64 | 2019-2023 | Camzyos |
| Boston Scientific Corporation | $178.37 | 2021-2025 | Watchman Access System, Watchman Flx |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamison Allen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.